Results 11 to 20 of about 365,679 (259)

Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose

Vaccines, 2022
With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce.
Po-Yu Chen, Bih-Ju Wu, Mei-Chin Su, Yen-Hsi Lin, Shu-Chiung Chiang, Jau-Ching Wu, Tzeng-Ji Chen, Yu-Chun Chen   +7 more
doaj   +1 more source

Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea [PDF]

Osong Public Health and Research Perspectives, 2022
Objectives This study aimed to disseminate information on coronavirus disease 2019 (COVID-19) vaccine safety among adolescents aged 12 to 17 years in the Republic of Korea.
Seontae Kim, Insob Hwang, Mijeong Ko, Yunhyung Kwon, Yeon-Kyeng Lee   +4 more
doaj   +1 more source

Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD

Vaccines, 2023
The disease burden of yellow fever virus infection (YFV) is quite high in the tropics where vaccination coverage is low. To date, vaccination is the most effective control strategy to mitigate and eliminate the burden of YF disease.
Flora de Andrade Gandolfi, Cassia Fernanda Estofolete, Marcia Catelan Wakai, Andreia Francesli Negri, Michela Dias Barcelos, Nikos Vasilakis, Mauricio Lacerda Nogueira   +6 more
doaj   +1 more source

The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessmentResearch in context

EClinicalMedicine, 2023
Summary: Background: Currently, melatonin is used to treat children and adolescents with insomnia without knowing the full extent of the short-term and long-term consequences.
Mina Nicole Händel, Henning Keinke Andersen, Anja Ussing, Anne Virring, Poul Jennum, Nanette Mol Debes, Torben Laursen, Lone Baandrup, Christina Gade, Jette Dettmann, Jonas Holm, Camilla Krogh, Kirsten Birkefoss, Simon Tarp, Mette Bliddal, Henriette Edemann-Callesen   +15 more
doaj   +1 more source

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis

Frontiers in Immunology, 2023
IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse ...
Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang   +6 more
doaj   +1 more source

Clinical trials facing “Serious Adverse Events” during the ongoing COVID-19 pandemic

Indian Journal of Medical and Paediatric Oncology, 2020
Aims and Objectives: The ongoing COVID-19 pandemic is having a profound impact on the current clinical trials. We wanted to document the extent of the disruption amongst Indian clinical trial sites.
Purvish M Parikh, Prashant Mehta, Krishna Kumar MVT, K Govind Babu   +3 more
doaj   +1 more source

Ocular adverse events in PD-1 and PD-L1 inhibitors

Journal for ImmunoTherapy of Cancer, 2021
Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors can cause unique immune-related adverse effects due to non-specific immunological activation.
James Murray, Howard Streicher, Elad Sharon, LeAnne Young, Shanda Finnigan, H Nida Sen, Helen X Chen   +6 more
doaj   +1 more source

Analysis of Centruroides (Scorpion) Immune F(ab’)2 (Equine) administration by slow intravenous push

Toxicology Communications, 2023
Scorpion envenomation is a common emergency department presentation in Arizona and antivenom is often administered . This study evaluates the safety of Centruroides (Scorpion) Immune F(ab’)2 (Equine) administered as a single-vial-serial dosing strategy ...
Clinton Peter, Spencer Kruggel, Aimee Mishler, Bikash Bhattarai, Dan Quan   +4 more
doaj   +1 more source

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Journal for ImmunoTherapy of Cancer, 2019
Following publication of the original article [1], the authors reported an error in their listed affiliations.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj   +1 more source

Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs

Stem Cell Research & Therapy, 2022
Background Mesenchymal stromal cells (MSCs) therapy for acute respiratory distress syndrome (ARDS) is an emerging treatment, but most of the current trials of MSCs stay in the animal experimental stage, and the safety and efficacy of MSCs in clinical ...
Jianbao Wang, Fenbin Luo, Ye Suo, Yuxin Zheng, Kaikai Chen, Deyuan You, Yuqi Liu   +6 more
doaj   +1 more source